Union Bancaire Privee UBP SA Purchases New Shares in Edwards Lifesciences Co. (NYSE:EW)

Union Bancaire Privee UBP SA acquired a new position in Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 14,802 shares of the medical research company’s stock, valued at approximately $1,120,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bowman & Co S.C. grew its holdings in shares of Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after acquiring an additional 148 shares in the last quarter. JFS Wealth Advisors LLC increased its position in shares of Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 166 shares during the last quarter. Seascape Capital Management raised its stake in shares of Edwards Lifesciences by 0.5% during the 3rd quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock worth $2,177,000 after purchasing an additional 174 shares during the period. Cooper Financial Group boosted its holdings in shares of Edwards Lifesciences by 2.8% in the 4th quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock worth $479,000 after buying an additional 175 shares during the last quarter. Finally, Martin Capital Advisors LLP grew its position in Edwards Lifesciences by 0.7% during the third quarter. Martin Capital Advisors LLP now owns 25,546 shares of the medical research company’s stock valued at $1,686,000 after buying an additional 186 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $69.21 on Tuesday. The company has a market capitalization of $40.82 billion, a P/E ratio of 9.99, a P/E/G ratio of 3.54 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a fifty day moving average of $72.33 and a 200-day moving average of $70.36.

Insiders Place Their Bets

In other news, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,717,841.12. The trade was a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,000 shares of company stock valued at $2,195,180 over the last 90 days. Insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on EW. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Evercore ISI dropped their price objective on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Morgan Stanley reissued an “equal weight” rating and issued a $70.00 target price on shares of Edwards Lifesciences in a research report on Friday, October 11th. Canaccord Genuity Group upped their price target on Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a research report on Thursday, December 5th. Finally, Wolfe Research lowered Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective for the company. in a report on Thursday, January 16th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Hold” and a consensus target price of $78.48.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.